Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement.
Tzong-Yun GerYu-Huei HuangRosaline Chung-Yee HuiTsen Fang TsaiHsien-Yi ChiuPublished in: Therapeutic advances in chronic disease (2019)
In a real-life clinical setting, the characteristics of nonreimbursed patients receiving secukinumab treatment differed from those of reimbursed patients. The PASI improvement for secukinumab was substantial but lower than that in clinical trials. The number and classes of prior biologic failures impact the treatment response to secukinumab.